Loading...
6660 logo

AIM Vaccine Co., Ltd.SEHK:6660 Stock Report

Market Cap HK$2.2b
Share Price
n/a
1Y-56.3%
7D1.2%
1D-6.7%
Portfolio Value
​
View

AIM Vaccine Co., Ltd.

SEHK:6660 Stock Report

Market Cap: HK$2.2b

AIM Vaccine (6660) Stock Overview

Engages in the research and development, manufacture, and sale of vaccine products for human use in the People’s Republic of China and internationally. More details

6660 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Risk Analysis

Earnings have declined by 13.4% per year over past 5 years

Volatile share price over the past 3 months compared to the Hong Kong market


6660 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW491,718 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
BL
BlackGoat
IN
Investingwilly
RO
RockeTeller
AG
Agricola
491,718 investors already sharing narratives
View all narratives

AIM Vaccine Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for AIM Vaccine
Historical stock prices
Current Share PriceHK$1.67
52 Week HighHK$6.01
52 Week LowHK$1.20
Beta0.10
1 Month Change-24.43%
3 Month Change-45.42%
1 Year Change-56.28%
3 Year Change-96.19%
5 Year Changen/a
Change since IPO-89.98%

Recent News & Updates

Recent updates

Analysis Article • Jul 24

AIM Vaccine Co., Ltd.'s (HKG:6660) Share Price Boosted 32% But Its Business Prospects Need A Lift Too

Despite an already strong run, AIM Vaccine Co., Ltd. ( HKG:6660 ) shares have been powering on, with a gain of 32% in...
Analysis Article • Apr 04

Take Care Before Jumping Onto AIM Vaccine Co., Ltd. (HKG:6660) Even Though It's 25% Cheaper

Unfortunately for some shareholders, the AIM Vaccine Co., Ltd. ( HKG:6660 ) share price has dived 25% in the last...
Analysis Article • Nov 15

Here's Why AIM Vaccine (HKG:6660) Can Afford Some Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article • Aug 24

Why Investors Shouldn't Be Surprised By AIM Vaccine Co., Ltd.'s (HKG:6660) 27% Share Price Plunge

Unfortunately for some shareholders, the AIM Vaccine Co., Ltd. ( HKG:6660 ) share price has dived 27% in the last...
Analysis Article • May 29

It's A Story Of Risk Vs Reward With AIM Vaccine Co., Ltd. (HKG:6660)

With a price-to-sales (or "P/S") ratio of 7x AIM Vaccine Co., Ltd. ( HKG:6660 ) may be sending bullish signals at the...
Analysis Article • Jun 09

Investor Optimism Abounds AIM Vaccine Co., Ltd. (HKG:6660) But Growth Is Lacking

AIM Vaccine Co., Ltd.'s ( HKG:6660 ) price-to-sales (or "P/S") ratio of 38.7x might make it look like a strong sell...

Shareholder Returns

6660HK BiotechsHK Market
7D1.2%10.5%-1.9%
1Y-56.3%-5.6%-4.5%

Return vs Industry: 6660 underperformed the Hong Kong Biotechs industry which returned -5.6% over the past year.

Return vs Market: 6660 underperformed the Hong Kong Market which returned -4.5% over the past year.

Price Volatility

Is 6660's price volatile compared to industry and market?
6660 volatility
6660 Average Weekly Movement12.8%
Biotechs Industry Average Movement8.9%
Market Average Movement7.4%
10% most volatile stocks in HK Market16.5%
10% least volatile stocks in HK Market3.5%

Stable Share Price: 6660's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: 6660's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of Hong Kong stocks.

About the Company

FoundedEmployeesCEOWebsite
20111,466Yan Zhouwww.aimbio.com

AIM Vaccine Co., Ltd. engages in the research and development, manufacture, and sale of vaccine products for human use in the People’s Republic of China and internationally. The company’s product pipeline includes tetravalent meningococcal conjugate vaccine, which is in phase IV clinical trial for meningococcal disease 13-Valent pneumonia conjugate and 23-valent pneumonia polysaccharide vaccine to treat pneumonia; iterative serum-free rabies vaccine; and bivalent Delta-Omicron BA.5 mRNA COVID-19 vaccine that is in phase III clinical trial to treat COVID-19 infection. It also offers tetravalent meningococcal polysaccharide and conjugate vaccine, which is in phase II trials for the treatment of meningococcal disease; and EV71-CA16 Bivalent HFMD vaccine.

AIM Vaccine Co., Ltd. Fundamentals Summary

How do AIM Vaccine's earnings and revenue compare to its market cap?
6660 fundamental statistics
Market capHK$2.20b
Earnings (TTM)-HK$780.99m
Revenue (TTM)HK$1.35b
1.5x
P/S Ratio
-2.6x
P/E Ratio

Is 6660 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6660 income statement (TTM)
RevenueCN¥1.17b
Cost of RevenueCN¥405.47m
Gross ProfitCN¥760.20m
Other ExpensesCN¥1.44b
Earnings-CN¥675.46m

Last Reported Earnings

Dec 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-0.55
Gross Margin65.22%
Net Profit Margin-57.95%
Debt/Equity Ratio59.4%

How did 6660 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/03 12:25
End of Day Share Price 2026/07/03 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

AIM Vaccine Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullFosun International Securities Limited
Tony RenMacquarie Research